3Methods for the analysis of neuronal plasticity and brain connectivity during neurological recovery1701-1703
6Six psychotropics for pre-symptomatic & early Alzheimer’s (MCI), Parkinson’s, and Huntington’s disease modiifcation1712-1726
7Neuroinlfammation, neurodegeneration and regeneration in multiple sclerosis：intercorrelated manifestations of the immune response1727-1730
8Targeting neuronal nitric oxide synthase as a valuable strategy for the therapy of neurological disorders1731-1734
10Astroglial heterogeneity：merely a neurobiological question? Or an opportunity for neuroprotection and regeneration atfer brain injury?1739-1741
13Reversing multiple age-related pathologies by controlling the senescence-associated secretory phenotype of stem cells1746-1747
14Adult neurogenesis and in vivo reprogramming：combining strategies for endogenous brain repair1748-1749
15Pretreatment of caffeine leads to partial neuroprotection in MPTP model of Parkinson’s disease1750-1751
16Molecular mechanisms of NMDA receptor-mediated excitotoxicity:implications for neuroprotective therapeutics for stroke1752-1753
17Targeting lysophospholipid signaling as a therapeutic approach towards improved peripheral nerve regeneration1754-1755
19Chaperoning glucocerebrosidase：a therapeutic strategy for both Gaucher disease and Parkinsonism1760-1761
